These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 16321761)

  • 1. Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
    Taphoorn MJ; Stupp R; Coens C; Osoba D; Kortmann R; van den Bent MJ; Mason W; Mirimanoff RO; Baumert BG; Eisenhauer E; Forsyth P; Bottomley A; ; ;
    Lancet Oncol; 2005 Dec; 6(12):937-44. PubMed ID: 16321761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
    Minniti G; Scaringi C; Baldoni A; Lanzetta G; De Sanctis V; Esposito V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):285-91. PubMed ID: 23642624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
    Pollom EL; Fujimoto D; Wynne J; Seiger K; Modlin LA; Jacobs LR; Azoulay M; von Eyben R; Tupper L; Gibbs IC; Hancock SL; Li G; Chang SD; Adler JR; Harsh GR; Harraher C; Nagpal S; Thomas RP; Recht LD; Choi CYH; Soltys SG
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):123-130. PubMed ID: 28586949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
    Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
    Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
    Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
    J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Reijneveld JC; Taphoorn MJB; Coens C; Bromberg JEC; Mason WP; Hoang-Xuan K; Ryan G; Hassel MB; Enting RH; Brandes AA; Wick A; Chinot O; Reni M; Kantor G; Thiessen B; Klein M; Verger E; Borchers C; Hau P; Back M; Smits A; Golfinopoulos V; Gorlia T; Bottomley A; Stupp R; Baumert BG
    Lancet Oncol; 2016 Nov; 17(11):1533-1542. PubMed ID: 27686943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
    Osoba D; Brada M; Yung WK; Prados M
    J Clin Oncol; 2000 Apr; 18(7):1481-91. PubMed ID: 10735896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
    Reddy K; Gaspar LE; Kavanagh BD; Waziri A; Damek DM; Ney D; Lillehei KO; Chen C
    J Neurooncol; 2013 Aug; 114(1):111-6. PubMed ID: 23729276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
    Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
    J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
    Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
    Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
    Taphoorn MJ; Henriksson R; Bottomley A; Cloughesy T; Wick W; Mason WP; Saran F; Nishikawa R; Hilton M; Theodore-Oklota C; Ravelo A; Chinot OL
    J Clin Oncol; 2015 Jul; 33(19):2166-75. PubMed ID: 26014298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
    Heutte N; Flechtner HH; Mounier N; Mellink WA; Meerwaldt JH; Eghbali H; van't Veer MB; Noordijk EM; Kluin-Nelemans JC; Lampka E; Thomas J; Lugtenburg PJ; Viterbo L; Carde P; Hagenbeek A; van der Maazen RW; Smit WG; Brice P; van Marwijk Kooy M; Baars JW; Poortmans P; Tirelli U; Leeksma OC; Tomsic R; Feugier P; Salles G; Gabarre J; Kersten MJ; Van Den Neste E; Creemers GJ; Gaillard I; Meijnders P; Tertian G; Reman O; Muller HP; Troncy J; Blanc M; Schroyens W; Voogt PJ; Wijermans P; Rieux C; Fermé C; Henry-Amar M;
    Lancet Oncol; 2009 Dec; 10(12):1160-70. PubMed ID: 19828373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
    Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
    Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
    J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study.
    Lombardi G; Bergo E; Del Bianco P; Bellu L; Pambuku A; Caccese M; Trentin L; Zagonel V
    Am J Clin Oncol; 2018 Dec; 41(12):1263-1271. PubMed ID: 29750673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
    Armstrong TS; Wefel JS; Wang M; Gilbert MR; Won M; Bottomley A; Mendoza TR; Coens C; Werner-Wasik M; Brachman DG; Choucair AK; Mehta M
    J Clin Oncol; 2013 Nov; 31(32):4076-84. PubMed ID: 24101048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
    Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
    Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.